Cardiff Oncology Inc (CRDF)

$4.17

-0.19

(-4.36%)▲

Market is closed - opens 7 PM, 24 Apr 2024

Insights on Cardiff Oncology Inc

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 83.0K → 156.0K (in $), with an average increase of 18.7% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -11.15M → -9.33M (in $), with an average increase of 9.4% per quarter

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 247.4% return, outperforming this stock by 299.4%

Performance

  • $4.06
    $4.41
    $4.17
    downward going graph

    2.64%

    Downside

    Day's Volatility :7.94%

    Upside

    5.44%

    downward going graph
  • $0.94
    $6.38
    $4.17
    downward going graph

    77.46%

    Downside

    52 Weeks Volatility :85.27%

    Upside

    34.64%

    downward going graph

Returns

PeriodCardiff Oncology IncSector (Health Care)Index (Russel 2000)
3 Months
175.25%
1.9%
0.0%
6 Months
334.38%
10.7%
0.0%
1 Year
185.62%
4.6%
-1.1%
3 Years
-55.45%
14.2%
-22.1%

Highlights

Market Capitalization
194.8M
Book Value
$1.56
Earnings Per Share (EPS)
-0.93
Wall Street Target Price
10.5
Profit Margin
0.0%
Operating Margin TTM
-6623.08%
Return On Assets TTM
-28.69%
Return On Equity TTM
-47.07%
Revenue TTM
488.0K
Revenue Per Share TTM
0.01
Quarterly Revenue Growth YOY
21.9%
Gross Profit TTM
-26.7M
EBITDA
-45.0M
Diluted Eps TTM
-0.93
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.97
EPS Estimate Next Year
-1.06
EPS Estimate Current Quarter
-0.28
EPS Estimate Next Quarter
-0.28

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Cardiff Oncology Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 151.8%

Current $4.17
Target $10.50

Company Financials

FY18Y/Y Change
Revenue
378.0K
↓ 25.15%
Net Income
-16.5M
↓ 33.91%
Net Profit Margin
-4.4K%
↑ 577.32%
FY19Y/Y Change
Revenue
245.0K
↓ 35.19%
Net Income
-16.2M
↓ 1.88%
Net Profit Margin
-6.6K%
↓ 2237.89%
FY20Y/Y Change
Revenue
366.0K
↑ 49.38%
Net Income
-19.3M
↑ 19.37%
Net Profit Margin
-5.3K%
↑ 1324.8%
FY21Y/Y Change
Revenue
359.0K
↓ 1.91%
Net Income
-27.7M
↑ 43.89%
Net Profit Margin
-7.7K%
↓ 2459.73%
FY22Y/Y Change
Revenue
386.0K
↑ 7.52%
Net Income
-37.5M
↑ 35.2%
Net Profit Margin
-9.7K%
↓ 1989.0%
FY23Y/Y Change
Revenue
488.0K
↑ 26.42%
Net Income
-41.4M
↑ 10.49%
Net Profit Margin
-8.5K%
↑ 1224.57%
Q3 FY22Q/Q Change
Revenue
93.0K
↑ 2.2%
Net Income
-8.1M
↓ 20.03%
Net Profit Margin
-8.8K%
↑ 2435.43%
Q4 FY22Q/Q Change
Revenue
128.0K
↑ 37.63%
Net Income
-8.0M
↓ 1.8%
Net Profit Margin
-6.3K%
↑ 2510.81%
Q1 FY23Q/Q Change
Revenue
83.0K
↓ 35.16%
Net Income
-10.4M
↑ 29.89%
Net Profit Margin
-12.5K%
↓ 6271.33%
Q2 FY23Q/Q Change
Revenue
108.0K
↑ 30.12%
Net Income
-11.2M
↑ 7.27%
Net Profit Margin
-10.3K%
↑ 2198.82%
Q3 FY23Q/Q Change
Revenue
141.0K
↑ 30.56%
Net Income
-9.7M
↓ 12.73%
Net Profit Margin
-6.9K%
↑ 3422.65%
Q4 FY23Q/Q Change
Revenue
156.0K
↑ 10.64%
Net Income
-9.3M
↓ 4.05%
Net Profit Margin
-6.0K%
↑ 916.16%
FY18Y/Y Change
Total Assets
14.2M
↑ 15.36%
Total Liabilities
4.1M
↓ 29.26%
FY19Y/Y Change
Total Assets
13.1M
↓ 7.66%
Total Liabilities
5.8M
↑ 41.29%
FY20Y/Y Change
Total Assets
134.7M
↑ 929.47%
Total Liabilities
6.6M
↑ 13.74%
FY21Y/Y Change
Total Assets
149.5M
↑ 11.0%
Total Liabilities
9.1M
↑ 38.93%
FY22Y/Y Change
Total Assets
116.2M
↓ 22.3%
Total Liabilities
9.8M
↑ 7.9%
FY23Y/Y Change
Total Assets
81.6M
↓ 29.74%
Total Liabilities
11.9M
↑ 20.82%
Q3 FY22Q/Q Change
Total Assets
123.6M
↓ 5.81%
Total Liabilities
10.4M
↓ 3.41%
Q4 FY22Q/Q Change
Total Assets
116.2M
↓ 6.02%
Total Liabilities
9.8M
↓ 5.48%
Q1 FY23Q/Q Change
Total Assets
106.5M
↓ 8.3%
Total Liabilities
10.0M
↑ 2.01%
Q2 FY23Q/Q Change
Total Assets
97.5M
↓ 8.54%
Total Liabilities
10.9M
↑ 8.26%
Q3 FY23Q/Q Change
Total Assets
88.5M
↓ 9.24%
Total Liabilities
10.6M
↓ 2.31%
Q4 FY23Q/Q Change
Total Assets
81.6M
↓ 7.7%
Total Liabilities
11.9M
↑ 11.98%
FY18Y/Y Change
Operating Cash Flow
-13.2M
↓ 43.3%
Investing Cash Flow
22.8K
↓ 99.9%
Financing Cash Flow
16.4M
↓ 357.2%
FY19Y/Y Change
Operating Cash Flow
-13.3M
↑ 0.52%
Investing Cash Flow
-67.6K
↓ 396.04%
Financing Cash Flow
12.1M
↓ 26.37%
FY20Y/Y Change
Operating Cash Flow
-16.3M
↑ 22.96%
Investing Cash Flow
-211.9K
↑ 213.33%
Financing Cash Flow
137.3M
↑ 1036.88%
FY21Y/Y Change
Operating Cash Flow
-23.0M
↑ 41.22%
Investing Cash Flow
-131.4M
↑ 61938.89%
Financing Cash Flow
35.5M
↓ 74.18%
FY22Y/Y Change
Operating Cash Flow
-33.8M
↑ 46.79%
Investing Cash Flow
38.1M
↓ 129.02%
Financing Cash Flow
75.0K
↓ 99.79%
Q3 FY22Q/Q Change
Operating Cash Flow
-7.5M
↑ 11.81%
Investing Cash Flow
5.2M
↓ 32.14%
Financing Cash Flow
75.0K
↓ 1350.0%
Q4 FY22Q/Q Change
Operating Cash Flow
-9.4M
↑ 25.43%
Investing Cash Flow
7.0M
↑ 35.97%
Financing Cash Flow
0.0
↓ 100.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-7.1M
↓ 17.63%
Investing Cash Flow
11.5M
↑ 56.69%
Financing Cash Flow
-6.0K
-

Technicals Summary

Sell

Neutral

Buy

Cardiff Oncology Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cardiff Oncology Inc
Cardiff Oncology Inc
-29.44%
334.38%
185.62%
-55.45%
17.13%
Moderna, Inc.
Moderna, Inc.
-2.26%
35.27%
-21.9%
-39.25%
318.83%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.59%
12.81%
13.84%
81.04%
166.5%
Novo Nordisk A/s
Novo Nordisk A/s
-0.32%
31.91%
50.92%
247.21%
431.9%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.67%
9.62%
21.65%
86.62%
134.62%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cardiff Oncology Inc
Cardiff Oncology Inc
NA
NA
NA
-0.97
-0.47
-0.29
NA
1.56
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.9
25.9
1.46
45.02
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
47.09
47.09
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.81
28.81
0.53
16.76
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cardiff Oncology Inc
Cardiff Oncology Inc
Buy
$194.8M
17.13%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$40.0B
318.83%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.8B
166.5%
25.9
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$558.9B
431.9%
47.09
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$103.4B
134.62%
28.81
36.68%

Institutional Holdings

  • Vanguard Group Inc

    4.28%

  • LAURION CAPITAL MANAGEMENT LP

    1.62%

  • BlackRock Inc

    1.60%

  • Geode Capital Management, LLC

    0.95%

  • Mccormack Advisors International

    0.85%

  • State Street Corporation

    0.31%

Corporate Announcements

  • Cardiff Oncology Inc Earnings

    Cardiff Oncology Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

trovagene is a precision medicine biotechnology company developing oncology therapeutics for improved cancer care by leveraging its proprietary precision cancer monitoring® (pcm) technology in tumor genomics. trovagene has broad intellectual property and proprietary technology to measure circulating tumor dna (ctdna) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies. trovagene offers its pcm technology at its clia/cap – accredited laboratory and plans to continue to vertically integrate its pcm technology with precision cancer therapeutics. trovagene's lead therapeutic asset is pcm-075, an oral, investigational drug and a highly-selective polo-like kinase 1 (plk1) inhibitor for the treatment of acute myeloid leukemia (aml). among the four members of the plk family, plk1 is recognized to be the fundamental component for cell division to take place correctly. most importantly, plk1 is only expressed in dividing cells, wh

Organization
Cardiff Oncology Inc
Employees
31
CEO
Dr. Mark Erlander Ph.D.
Industry
Health Services

Discover More

FAQs